In term infants, pulmonary hypertension is often associated with relatively recognizable disturbances in the transition from fetal to newborn circulation. In preterm infants, that transition is complicated by immature lungs, incomplete vascular development, inflammation, mechanical ventilation, infection, patent ductus arteriosus and unstable cardiac function. These factors can act together to increase resistance in the pulmonary circulation, limiting blood flow through the lungs and reducing oxygen transfer. The result may be severe hypoxemia that does not respond predictably to conventional respiratory support.

The review by Mohamed M. Elgendy and Sandeep Nath describes several possible hemodynamic phenotypes behind acute pulmonary hypertension. Some infants may have severely elevated pulmonary vascular resistance, which restricts blood flow from the right ventricle into the lungs. Others may have right ventricular dysfunction, left ventricular impairment or inadequate systemic blood flow. A large patent ductus arteriosus can further alter the direction and volume of blood flow between the pulmonary artery and aorta. In such cases, the same oxygen saturation pattern may arise from entirely different mechanisms, making a uniform treatment strategy potentially ineffective or harmful.

Bronchopulmonary dysplasia is another major part of the problem. Premature lungs may contain fewer and smaller pulmonary vessels, while ongoing inflammation and oxygen exposure can damage the developing vascular bed. This structural limitation can raise pulmonary vascular resistance and place additional stress on the right ventricle. At the same time, areas of collapsed or poorly aerated lung can create ventilation–perfusion mismatch, in which blood reaches regions that cannot adequately oxygenate it. The combination of abnormal lung mechanics and cardiovascular strain can rapidly progress to hypoxic respiratory failure.

For clinicians, distinguishing these mechanisms requires more than measuring oxygen saturation or blood pressure. The authors highlight the growing importance of targeted neonatal echocardiography and functional echocardiographic assessment. These bedside techniques can evaluate right and left ventricular performance, estimate pulmonary pressures, examine the direction of ductal shunting and identify whether the heart is failing to deliver sufficient systemic blood flow. Serial examinations are particularly important because the physiology of a critically ill preterm infant can change quickly in response to ventilation, fluids, infection, medications or changes in ductal flow.

One of the most controversial treatments is inhaled nitric oxide, or iNO. Nitric oxide is a naturally occurring signaling molecule that relaxes smooth muscle in the pulmonary arteries. When inhaled, it reaches ventilated areas of the lung and can selectively widen nearby pulmonary vessels, potentially improving the match between ventilation and blood flow. In carefully selected infants with pulmonary hypertension and severe oxygenation failure, this mechanism may produce a rapid rise in oxygen levels and reduce the pressure burden on the right ventricle.

However, the review stresses that short-term improvement in oxygenation is not the same as improved survival or healthier development. Randomized clinical trials in preterm infants have not shown that routine iNO treatment reduces mortality or the incidence of bronchopulmonary dysplasia. Concerns have also persisted about a possible increase in severe intraventricular hemorrhage, a serious form of bleeding into the immature brain. Because premature infants have fragile cerebral blood vessels and unstable cerebral blood flow, any therapy that alters vascular resistance or produces abrupt hemodynamic changes must be used with considerable caution.

The evidence therefore does not support treating every preterm infant with hypoxic respiratory failure as though pulmonary hypertension were the same condition in each case. iNO may be considered when echocardiography and the clinical picture indicate significant pulmonary vascular constriction, particularly when oxygenation remains poor despite optimized lung recruitment and ventilation. But indiscriminate use could expose infants to risk without addressing the actual cause of their deterioration. If the dominant problem is left ventricular dysfunction, excessive pulmonary blood flow through a ductus or inadequate systemic perfusion, pulmonary vasodilation alone may fail to correct the underlying physiology.

Vasoactive and inotropic medications may have an important role when cardiovascular dysfunction accompanies pulmonary hypertension. Inotropes can increase the force of cardiac contraction, while vasoactive agents can alter systemic vascular tone and support blood pressure. Their effects, however, are not interchangeable. Raising systemic vascular resistance may improve coronary and cerebral perfusion in one infant but increase cardiac workload in another. Similarly, increasing contractility may support a failing ventricle but also raise myocardial oxygen demand. The review argues that these therapies should be selected according to the infant’s measured hemodynamic phenotype rather than administered through a generalized protocol.

The authors ultimately call for a physiology-based approach that combines careful clinical observation, advanced respiratory support, serial functional echocardiography and targeted cardiovascular treatment. Such an approach recognizes that pulmonary hypertension in preterm infants is a dynamic interaction between the lungs, pulmonary vessels, heart and systemic circulation. Although iNO can offer meaningful oxygenation benefits in selected cases, it should not be viewed as a universal solution. More precise phenotyping, standardized bedside assessment and future trials focused on clinically relevant outcomes will be essential to determine which infants benefit from specific therapies—and which may be placed at risk by them.

Subject of Research: Pulmonary hypertension and acute hypoxic respiratory failure in preterm neonates

Article Title: Pulmonary hypertension and acute hypoxic respiratory failure in preterm neonates

Article References: Elgendy, M.M., Nath, S. Pulmonary hypertension and acute hypoxic respiratory failure in preterm neonates. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02858-9

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02858-9

Keywords: pulmonary hypertension, preterm infants, hypoxic respiratory failure, bronchopulmonary dysplasia, inhaled nitric oxide, neonatal echocardiography, pulmonary vascular resistance, vasoactive agents, intraventricular hemorrhage

Patent ductus arteriosus, a condition characterized by a persistent opening between the major blood vessels leading from the heart, commonly affects preterm infants. This condition can result in severe complications, including heart failure and chronic lung disease, if left untreated. Traditional interventions often involve invasive surgery or pharmacological treatments with significant risks, especially in infants born at the edge of viability.

The recent study by Hundscheid, van den Berg, and de Boode, published in Pediatric Research, elucidates the feasibility and safety of performing PDA closure directly at the infant’s bedside using ultrasound-guided techniques. This bedside intervention circumvents the need for transporting critically ill infants to operating rooms or catheterization labs, significantly minimizing procedural risk and stress on these vulnerable patients.

Ultrasound guidance plays a pivotal role in this technique. It allows clinicians to visualize the cardiac structures in real-time, facilitating precise deployment of closure devices without the need for fluoroscopy or general anesthesia. This real-time imaging ensures that the procedure can be performed swiftly and effectively, with continuous monitoring of the infant’s hemodynamic status throughout the intervention.

One of the remarkable advantages of this approach is its potential to reduce the duration of exposure to sedatives and general anesthesia, which are known to carry risks of neurodevelopmental impairment in premature infants. By enabling closure at the bedside, the procedure advocates for a gentler, more patient-centric care model that prioritizes safety without compromising therapeutic outcomes.

The researchers systematically assessed the procedural outcomes, monitoring for complications such as device embolization, residual shunting, or vascular injury. Initial findings underscore the procedure’s high safety profile, with no major adverse events reported in the small cohort studied. Furthermore, ultrasound-enabled visualization enhanced the precision of device placement, minimizing the risk of incomplete closure or damage to adjacent cardiac structures.

Critical to the success of this method is the collaboration between neonatologists, pediatric cardiologists, and sonographers, emphasizing a multidisciplinary approach in managing complex neonatal heart conditions. This synergy is crucial, as expertise in ultrasonography and neonatal physiology intersect to optimize patient outcomes during such precarious interventions.

Moreover, the bedside PDA closure technique aligns with the growing trend toward minimally invasive procedures in neonatal care, reflecting a paradigm shift that favors less intrusiveness and faster recovery times. Implementing such innovations may lead to shorter hospital stays and decreased healthcare costs, a substantial benefit for overstretched neonatal units globally.

Additionally, the study paves the way for further refinement of devices specifically designed for bedside PDA closure. Current closure devices, while effective, were initially engineered for older populations and require adaptation to fit the unique anatomical and physiological needs of extreme preterm infants. Future research is anticipated to drive the development of smaller, more adaptable devices to enhance procedural success and safety.

This protocol also highlights the evolving role of high-resolution ultrasonography in neonatal intensive care beyond diagnostic use, serving as an interventional tool that bridges the gap between imaging and therapy. It challenges previous limitations, demonstrating that with adequate training and technological advancements, ultrasound can empower safer bedside interventions.

While the initial study provides promising results, the authors acknowledge the necessity for larger, multicenter trials to validate these findings comprehensively. Broader implementation will require standardized protocols, operator training, and rigorous assessment of long-term neurodevelopmental outcomes to ensure that bedside PDA closure becomes an established standard of care.

Importantly, the psychological and physiological benefits for infants and families cannot be overstated. Avoiding transport and invasive procedures reduces parental stress and supports a more continuous bonding experience during critical periods of infant development, which can positively influence long-term well-being.

Furthermore, this innovation carries implications for healthcare systems in resource-limited settings where access to comprehensive operating facilities is limited. Bedside PDA closure using portable ultrasound machines could democratize advanced neonatal cardiac care, ensuring more infants receive timely, effective treatment regardless of geographic constraints.

In summary, the ultrasonic bedside closure of patent ductus arteriosus in extreme preterm infants marks a thrilling milestone in neonatal medicine. It promises safer, more efficient, and patient-centric care, leveraging technology to overcome longstanding challenges in managing this fragile population. As ongoing research builds on these foundations, the future of neonatal cardiac interventions looks increasingly bright and accessible.

Subject of Research: Bedside closure of patent ductus arteriosus in extreme preterm infants using ultrasound guidance.

Article Title: Bedside patent ductus arteriosus closure in extreme preterm infants—safe and (ultra)sound?.

Article References:
Hundscheid, T., van den Berg, G. & de Boode, W.P. Bedside patent ductus arteriosus closure in extreme preterm infants—safe and (ultra)sound?. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05180-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-05180-4

Patent ductus arteriosus, a common cardiovascular condition in premature neonates, involves the persistence of the ductus arteriosus—a fetal vessel connecting the pulmonary artery to the aorta—beyond birth. This persistence often results in abnormal blood flow patterns that can compromise the oxygenation and nutrient supply to critical organs, particularly the brain and gastrointestinal tract. The research team led by Mifflin et al. harnessed cerebral and intestinal Doppler imaging to reveal how variations in PDA shunt characteristics manifest as altered hemodynamic profiles in affected infants.

Doppler ultrasound, a non-invasive imaging modality, records blood flow velocity and direction by detecting frequency shifts in reflected ultrasound waves. In this study, it served as a pivotal tool for mapping vascular resistance and flow patterns in the anterior cerebral artery and superior mesenteric artery. By correlating shunt flow direction and magnitude with cerebral and intestinal perfusion, the investigators could parse out how PDA influences organ perfusion differentially, advancing understanding beyond the binary presence or absence of the ductus.

One of the compelling findings is the demonstration of distinct Doppler flow waveforms that correspond to the directionality and volume of PDA shunting. Left-to-right shunts, the more common type, were associated with increased diastolic flow in cerebral vessels, indicative of altered cerebral autoregulation and potential vulnerability to ischemic injury. Conversely, right-to-left shunting reshaped intestinal vascular profiles, hinting at compromised mesenteric perfusion and a potential mechanistic link to necrotizing enterocolitis, a severe gastrointestinal complication in preterm infants.

The study delves deeply into the pathophysiological implications of these altered flow patterns. Impaired cerebral hemodynamics in preterm infants have long been implicated in neurodevelopmental delays and cerebral palsy. By elucidating specific Doppler signatures associated with PDA shunting, clinicians now gain a non-invasive window into real-time cerebral perfusion status, enabling earlier identification of infants at risk for adverse neurological outcomes and facilitating timely therapeutic strategies.

Similarly, the intestinal Doppler findings carry significant clinical weight. The superior mesenteric artery supplies the small bowel—a region highly sensitive to ischemic stress. Recognition that PDA shunt direction impacts mesenteric blood flow paves the way for more nuanced monitoring and management of feeding tolerance and intestinal health in preterm neonates, potentially reducing morbidity and mortality associated with intestinal ischemia.

The methodology behind these discoveries involved comprehensive Doppler ultrasound assessments in a cohort of very low birth weight preterm infants diagnosed with PDA via echocardiography. The researchers meticulously categorized PDA shunt characteristics based on flow direction and velocity waveforms, cross-referencing these with cerebral and intestinal Doppler measurements. This approach allowed for a detailed characterization of vascular resistance changes and highlighted the dynamic nature of organ-specific blood flow modulation in the setting of congenital heart anomalies.

What sets this study apart is its multi-organ focus combined with advanced imaging analytics. Prior research often concentrated solely on either cerebral or intestinal hemodynamics but rarely correlated both simultaneously with PDA shunt characteristics. This holistic perspective enhances the understanding of systemic repercussions in preterm infants with PDA and underscores the importance of integrated cardiovascular and neurogastroenterological monitoring.

Clinically, these insights hold promise for transforming PDA management protocols. By differentiating infants with deleterious flow patterns, neonatologists can refine decision-making about pharmacological or surgical PDA closure interventions, weighing risks and benefits with improved precision. The ability to non-invasively track cerebral and intestinal perfusion longitudinally also aids in assessing treatment efficacy and guiding supportive care measures such as blood pressure optimization and nutritional strategies.

Furthermore, this research highlights the potential for Doppler ultrasound as a routine bedside tool in neonatal intensive care units (NICUs). Its non-invasive nature, repeatability, and immediate feedback can empower clinicians with real-time hemodynamic data, fostering individualized medicine approaches. Future integration with artificial intelligence algorithms may augment pattern recognition and risk stratification, driving the field toward predictive neonatology.

In addition to its clinical ramifications, the study raises intriguing biological questions regarding vascular regulation in immature organ systems. PDA-induced alterations in shear stress, endothelial function, and neurovascular coupling mechanisms deserve further investigation to unravel the molecular underpinnings of observed Doppler patterns. Such insights could spur novel therapeutic avenues targeting vascular biology alongside mechanical PDA closure.

The study also emphasizes the importance of early diagnosis and continuous monitoring in preterm infants, a population highly susceptible to rapid hemodynamic fluctuations. Temporal changes in Doppler flow waveforms may serve as biomarkers of disease progression or resolution, guiding timing of interventions to optimize outcomes. The inclusion of both cerebral and intestinal circulations provides a comprehensive organ perfusion map crucial to holistic neonatal care.

Importantly, the researchers acknowledge certain limitations in their work, including the inherent technical challenges of Doppler measurements in tiny preterm vessels, inter-operator variability, and the influence of confounding factors such as respiratory support and pharmacologic agents. Nevertheless, the consistency of their findings across a sizable sample provides robust support for their conclusions and lays the foundation for larger multicenter trials.

Looking ahead, the integration of this vascular Doppler profiling with other modalities such as near-infrared spectroscopy (NIRS) and magnetic resonance imaging (MRI) could enhance multi-dimensional assessments of tissue oxygenation and perfusion metabolism. Such multi-modal strategies would deepen insights into the complex interplay between PDA shunting, organ injury, and developmental outcomes.

In summary, this landmark study by Mifflin and colleagues propels neonatal cardiology and neurogastroenterology into a new era of precision diagnostics. By decoding the cerebral and intestinal Doppler signatures linked with PDA shunt characteristics, the research unlocks a vital pathway toward mitigating morbidity in preterm infants. The findings resonate with the urgent clinical imperative to safeguard the most fragile patients through innovation, vigilance, and interdisciplinary collaboration.

As neonatal intensive care advances, these discoveries underscore the principle that understanding vascular flow dynamics transcends mere anatomy. It challenges clinicians and scientists to comprehend how subtle hemodynamic shifts reverberate through developing organ systems, shaping lifelong health trajectories. This research illuminates a path toward customized care that harmonizes technological prowess with compassionate clinical insight.

Delivering a powerful amalgam of technical expertise and clinical vision, the study exemplifies how cutting-edge ultrasound technology, combined with rigorous scientific inquiry, can transform patient care. As PDA remains a persistent challenge in prematurity, these new insights instill hope for reducing neurological compromise and gastrointestinal injury—critical milestones on the journey to healthier futures for the tiniest patients.

Subject of Research: Hemodynamic effects of patent ductus arteriosus shunting on cerebral and intestinal blood flow in preterm infants.

Article Title: Cerebral and intestinal Doppler patterns according to patent ductus arteriosus shunt characteristics in preterm infants.

Article References:
Mifflin, J., Makoni, M., Chatmethakul, T. et al. Cerebral and intestinal Doppler patterns according to patent ductus arteriosus shunt characteristics in preterm infants. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02505-9

Image Credits: AI Generated

DOI: 24 November 2025

Premature birth, particularly prior to 28 weeks of gestation, predisposes neonates to an alarmingly increased risk of kidney disease in later life. Statistics reveal that these infants are two to four times more likely to develop CKD, with early signs detectable as soon as two years of age. The kidney’s vulnerability in this population is not merely a consequence of underdevelopment but results from multifaceted etiologies that include shared risk factors overlapping with acute kidney injury (AKI). These risk factors encompass hypoxia, hemodynamic instability, and exposure to nephrotoxic medications, converging to sabotage nephrogenesis and kidney resilience.

Amidst these challenges, the presence of a PDA introduces additional hemodynamic complications. For the uninitiated, the ductus arteriosus is a fetal blood vessel that connects the pulmonary artery to the aorta, allowing fetal blood to bypass the non-ventilated lungs. Normally, this vessel closes in the immediate postnatal period; however, in many preterm infants, the ductus remains patent. This persistent shunt creates systemic and pulmonary blood flow imbalances that can strain immature organs. The kidney, highly sensitive to hemodynamic shifts, may suffer from altered perfusion, escalating the risk of injury and long-term dysfunction.

Despite the plausibility of these effects, the direct link between PDA pathophysiology and long-term kidney outcomes has remained elusive. Only recently has research explicitly focused on understanding how PDA and its management techniques impact renal function beyond the neonatal period. In one pivotal retrospective study, researchers compared renal outcomes at two years of age in infants treated for PDA versus those who remained untreated. Surprisingly, the findings demonstrated no significant difference in estimated glomerular filtration rate (eGFR) or albumin-to-creatinine ratios, well-established measures of kidney function.

However, the study unveiled a fascinating paradox—infants who received PDA treatment exhibited notably lower incidences of hypertension, defined as systolic blood pressure above the 90th percentile for their age. This observation suggests that medical or surgical closure of the PDA may confer protective effects not immediately visible through conventional renal biomarkers. Hypertension, a significant risk factor for progressive CKD, when mitigated, could indicate more subtle nephron preservation or improved systemic vascular regulation influenced by PDA management. These findings underscore the complexity of the PDA-kidney relationship, hinting that benefits of intervention may transcend traditional renal function metrics.

Yet, these valuable insights come with important caveats. The study’s retrospective design inherently limits the ability to establish causation, and the absence of comprehensive echocardiographic data to grade PDA shunt severity reduces the precision of comparisons. Additionally, the heterogeneity in treatment protocols—ranging from conservative watchful waiting to pharmacological and surgical intervention—complicates the interpretation of results. Such methodological constraints highlight the urgent need for prospective, controlled trials with standardized assessments to unravel the mechanistic pathways linking PDA physiology to renal health.

At the crux of the matter is the concept of nephron endowment— the total number of functional filtering units formed during kidney development. Prematurity already truncates nephrogenesis, which normally continues until about 36 weeks gestation. PDA-induced circulatory variations could exacerbate nephron loss or malformation, effectively “stealing nephrons” and compromising kidney reserve. Compounding this effect, hemodynamic instability can precipitate recurrent kidney ischemia, inflammation, and fibrosis, creating a protracted trajectory toward CKD. Understanding how PDA affects nephron trajectory represents a frontier in perinatal nephrology.

Unfortunately, longitudinal data extending beyond early childhood into adulthood are nearly nonexistent, leaving a critical knowledge gap regarding the lifelong kidney consequences of PDA. Given that CKD and hypertension carry significant morbidity and mortality, elucidating these pathways could guide neonatal care paradigms to optimize both heart and kidney protection. The potential for early PDA interventions to recalibrate risk profiles holds profound implications for clinical guidelines and parental counseling alike.

Emerging evidence also calls for a multidisciplinary approach integrating neonatologists, pediatric nephrologists, and cardiologists to tailor PDA management according to individual risk profiles. Echocardiographic measures of shunt volume and impact on systemic blood flow could inform decisions to intervene early versus monitor conservatively. Such tailored strategies might mitigate renal insults without exposing infants to unnecessary treatment risks, balancing cardiac and renal outcomes sensitively.

Pharmacologic agents used to close the PDA, such as indomethacin or ibuprofen, carry their own nephrotoxic potential, complicating the risk-benefit calculus. Therefore, innovations in therapeutic modalities that minimize renal side effects are eagerly awaited. Additionally, the role of supportive care measures, such as optimizing fluid management and avoiding nephrotoxins, remains foundational in safeguarding the fragile kidneys of preterm infants.

Intriguingly, there is growing interest in incorporating biomarkers of kidney injury and repair to monitor subclinical changes in renal health. Novel urinary and blood markers could help detect early kidney stress before overt dysfunction emerges, allowing timely adjustments in treatment strategies. In research settings, these biomarkers may elucidate the mechanistic underpinnings of PDA-related nephron loss or preservation over time.

From a broader perspective, this evolving understanding of PDA’s impact on renal health challenges us to reconceptualize neonatal care beyond survival and immediate outcomes. The intertwined fate of the heart and kidneys in preterm infants exemplifies the principle that organ systems do not exist in isolation. Thus, comprehensive models of neonatal care must integrate insights from cardiology, nephrology, and developmental biology to ensure holistic, long-term health optimization.

As science advances, it becomes increasingly clear that PDA is not merely a transient cardiac anomaly but a potential origin point for chronic renal vulnerability. This paradigm shift opens avenues for preventive strategies, early interventions, and personalized medicine approaches designed to preserve nephron number and function. Ultimately, these efforts aim to break the chain linking prematurity, PDA, and CKD, offering hope for improved quality of life decades after the neonatal period.

In light of these developments, the medical community and researchers are called upon to prioritize longitudinal cohort studies that track renal outcomes into adolescence and adulthood. Such data will be instrumental in validating early findings and refining treatment algorithms. Additionally, investment in experimental models that simulate PDA physiology and its renal repercussions can expedite discovery of protective mechanisms and therapeutic targets.

The unfolding story of PDA and neonatal kidney health exemplifies the intricate interplay of developmental physiology and disease. It urges vigilance in clinical practice and fuels a quest for knowledge that promises to transform care for the smallest and most vulnerable patients—ushering in a new era where saving nephrons today safeguards the lives and wellbeing of adults tomorrow.

Subject of Research: Impact of patent ductus arteriosus physiology on neonatal kidney health and long-term kidney outcomes.

Article Title: Stealing nephrons—a review on how patent ductus arteriosus physiology impacts neonatal kidney health.

Article References:
Condit, P.E., Harshman, L.A., Soranno, D.E. et al. Stealing nephrons—a review on how patent ductus arteriosus physiology impacts neonatal kidney health. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02477-w

Image Credits: AI Generated

DOI: 05 November 2025

Keywords: Patent Ductus Arteriosus, Neonatal Kidney Health, Prematurity, Chronic Kidney Disease, Nephrogenesis, Hypertension, Neonatal Cardiology, Renal Function, Neonatal Intensive Care, Pediatric Nephrology